TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Breast Cancer Research and Treatment

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 18043895
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

  2005cited by this paper
• Non-Smad TGF-beta signals.

  2005cited by this paper
• OXIDATION OF TAMOXIFEN BY HUMAN FLAVIN-CONTAINING MONOOXYGENASE (FMO) 1 AND FMO3 TO TAMOXIFEN-N-OXIDE AND ITS NOVEL REDUCTION BACK TO TAMOXIFEN BY HUMAN CYTOCHROMES P450 AND HEMOGLOBIN

  2005cited by this paper
• Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen

  2004cited by this paper
• Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6

  2004cited by this paper
• Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells.

  2004cited by this paper
• Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

  2003cited by this paper
• Effects of tamoxifen on transcriptional level of transforming growth factor beta (TGF-beta) isoforms 1 and 2 in tumor tissue during primary treatment of patients with breast cancer.

  2003cited by this paper
• Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity.

  2003cited by this paper
• Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

  2003cited by this paper
• The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.

  2002cited by this paper
• Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA.

  2002cited by this paper
• Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.

  2002cited by this paper
• A basic conceptual and practical overview of interactions with highly prescribed drugs.

  2002cited by this paper
• Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours

  2000cited by this paper
• Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.

  1998cited by this paper
• Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin

  1998cited by this paper
• Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes.

  1997cited by this paper
• New Highly Stereoselective Synthesis of (Z)-4-Hydroxytamoxifen and (Z)-4-Hydroxytoremifene via McMurry Reaction.

  1996cited by this paper
• Regulation and role of TGF beta production in breast cancer.

  1996cited by this paper
• The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.

  1995cited by this paper
• Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen.

  1995cited by this paper
• Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation.

  1993cited by this paper
• Activity of tamoxifen and its metabolites on endocrine-dependent and endocrine-independent breast cancer cells.

  1991cited by this paper
• Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment.

  1991cited by this paper
• Induction of Transforming Growth Factor β by the Antiestrogens Droloxifene, Tamoxifen, and Toremifene in MCF‐7 Cells

  1991cited by this paper
• Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide.

  1990cited by this paper
• Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer.

  1990cited by this paper
• Tamoxifen metabolism: pharmacokinetic and in vitro study.

  1989cited by this paper
• Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines.

  1989cited by this paper
• Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.

  1989cited by this paper
• Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours.

  1987cited by this paper
• Analysis of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen levels in cytosol and KCl-nuclear extracts of breast tumours from tamoxifen treated patients by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM).

  1987cited by this paper
• Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen.

  1984cited by this paper
• Identification and biological activity of tamoxifen metabolites in human serum.

  1983cited by this paper
• Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth.

  1982cited by this paper
• Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer.

  1981cited by this paper
• A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.

  1977cited by this paper

• Mono-CYP CHO Model: A Recombinant Chinese Hamster Ovary Cell Platform for Investigating CYP-Specific Tamoxifen Metabolism

  2025cites this paper
• CYP2C19*17 association with higher plasma 4-hydroxy tamoxifen in Pakistani (estrogen-positive) breast cancer patients

  2023cites this paper
• Nanotechnology‐based electrochemical biosensors for monitoring breast cancer biomarkers

  2022cites this paper
• The crosstalk of the human microbiome in breast and colon cancer: A metabolomics analysis.

  2022cites this paper
• The molecular genetic make-up of male breast cancer.

  2019cites this paper
• NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

  2018cites this paper
• Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People

  2018cites this paper
• Effects of the GTPase Rab31 on breast cancer cell proliferation, adhesion, and expression of other tumor-associated genes

  2014cites this paper
• Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ.

  2013cites this paper
• Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites.

  2012cites this paper
• Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen.

  2012cites this paper
• Transforming growth factor beta 2: a predictive marker for breast cancer.

  2011cites this paper
• Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

  2011cites this paper
• Coprescription of tamoxifen and medications that inhibit CYP2D6.

  2010cites this paper
• Molekularne wyznaczniki raka piersi Inicjacja i promocja - część I

  2010cites this paper
• Tamoxifen induces pleiotrophic changes in mammary stroma resulting in extracellular matrix that suppresses transformed phenotypes

  2009cites this paper
• Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?

  2009cites this paper
• Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

  2009cites this paper
• A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.

  2008cites this paper
• Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance

  2008cites this paper
• Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response

  2008cites this paper
• Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer

  2008cites this paper